← Chularat Hospital overview

Chularat Hospital vs Encompass Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chularat Hospital Public Company Limited (CHG.BK)

Q3 2026
▲2▼1

Hospital sector swings from sell to buy as SSO rate decision looms

  • Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded CHG to sell, warning that 16 new premium clinics inside public hospitals will steal middle-income and foreign patients, sparking price wars, higher marketing costs, doctor poaching and tougher insurer bargaining. That squeezes CHG's revenue and margins, pushing the stock down.

    This is the main negative force on CHG this period, directly cutting its earnings estimates and rating.

  • KKPS turns overweight on hospitals, buy CHG at 2 baht KKPS upgraded the hospital sector to overweight and rated CHG a buy with a 2 baht target. It argues government budget limits will push state health costs onto private hospitals, adding over 100 billion baht of potential revenue, while sector earnings have passed their trough and trade cheaply versus regional peers.

    This is the strongest new positive catalyst, reversing the earlier sell call and giving a concrete upside target.

  • SSO service-rate decision pending; CHG rated hold Kasikorn Securities said a delay in electing the Social Security Office board won't stop a review of medical service rates, with a key meeting on October 5. It rates CHG a hold with a 1.69 baht target, noting that if SSO doesn't raise rates at all, CHG's value would fall about 4%.

    This is the key regulatory swing factor for CHG's revenue, with a clear downside if the rate rise fails.

  • Maybank and Yuanta name CHG a top pick on stable revenue Maybank raised its 2026 SET target and named CHG a top hospital pick, citing stable revenue and specific supporting factors. Yuanta then flagged CHG among stocks with strong third-quarter profit momentum, helped by domestic and tourism recovery from a low 2025 base.

    These broker endorsements add fresh demand-side support and reinforce the positive turn in sentiment.

August 2026
▲2▼1

Hospital sector swings from sell to buy as SSO rate decision looms

  • Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded CHG to sell, warning that 16 new premium clinics inside public hospitals will steal middle-income and foreign patients, sparking price wars, higher marketing costs, doctor poaching and tougher insurer bargaining. That squeezes CHG's revenue and margins, pushing the stock down.

    This is the main negative force on CHG this period, directly cutting its earnings estimates and rating.

  • KKPS turns overweight on hospitals, buy CHG at 2 baht KKPS upgraded the hospital sector to overweight and rated CHG a buy with a 2 baht target. It argues government budget limits will push state health costs onto private hospitals, adding over 100 billion baht of potential revenue, while sector earnings have passed their trough and trade cheaply versus regional peers.

    This is the strongest new positive catalyst, reversing the earlier sell call and giving a concrete upside target.

  • SSO service-rate decision pending; CHG rated hold Kasikorn Securities said a delay in electing the Social Security Office board won't stop a review of medical service rates, with a key meeting on October 5. It rates CHG a hold with a 1.69 baht target, noting that if SSO doesn't raise rates at all, CHG's value would fall about 4%.

    This is the key regulatory swing factor for CHG's revenue, with a clear downside if the rate rise fails.

  • Maybank and Yuanta name CHG a top pick on stable revenue Maybank raised its 2026 SET target and named CHG a top hospital pick, citing stable revenue and specific supporting factors. Yuanta then flagged CHG among stocks with strong third-quarter profit momentum, helped by domestic and tourism recovery from a low 2025 base.

    These broker endorsements add fresh demand-side support and reinforce the positive turn in sentiment.

Latest
▲2▼1

Hospital sector swings from sell to buy as SSO rate decision looms

  • Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded CHG to sell, warning that 16 new premium clinics inside public hospitals will steal middle-income and foreign patients, sparking price wars, higher marketing costs, doctor poaching and tougher insurer bargaining. That squeezes CHG's revenue and margins, pushing the stock down.

    This is the main negative force on CHG this period, directly cutting its earnings estimates and rating.

  • KKPS turns overweight on hospitals, buy CHG at 2 baht KKPS upgraded the hospital sector to overweight and rated CHG a buy with a 2 baht target. It argues government budget limits will push state health costs onto private hospitals, adding over 100 billion baht of potential revenue, while sector earnings have passed their trough and trade cheaply versus regional peers.

    This is the strongest new positive catalyst, reversing the earlier sell call and giving a concrete upside target.

  • SSO service-rate decision pending; CHG rated hold Kasikorn Securities said a delay in electing the Social Security Office board won't stop a review of medical service rates, with a key meeting on October 5. It rates CHG a hold with a 1.69 baht target, noting that if SSO doesn't raise rates at all, CHG's value would fall about 4%.

    This is the key regulatory swing factor for CHG's revenue, with a clear downside if the rate rise fails.

  • Maybank and Yuanta name CHG a top pick on stable revenue Maybank raised its 2026 SET target and named CHG a top hospital pick, citing stable revenue and specific supporting factors. Yuanta then flagged CHG among stocks with strong third-quarter profit momentum, helped by domestic and tourism recovery from a low 2025 base.

    These broker endorsements add fresh demand-side support and reinforce the positive turn in sentiment.

Encompass Health Corp (EHC)

Q3 2026
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

August 2026
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

Latest
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.